Gliptins for Type 2 Diabetes
From New Treatment Wiki
Gliptins are novel therapeutic agents that inhibit the ubiquitous enzyme, Dipeptidyl Peptidase-IV (DPP-IV) in patients with type 2 diabetes.
DPP-IV rapidly metabolises the incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) resulting in their reduced bioavailability and rapid inactivation in the circulation. GLP-1 and GIP are incretin hormones, released in response to nutrient stimulation and act to augment nutrient-induced insulin release in a glucose dependent manner.
Contents |
Latest treatments for Gliptins
The latest treatments and drugs based on gliptins include
- Januvia (sitagliptin) for Type 2 Diabetes
- Glavus (vildagliptin) for Type 2 Diabetes
- Denagliptin for Type 2 Diabetes
Ongoing clinical trials for Gliptins
- Type 2 Diabetes study in North Carolina investigating dutogliptin for patients who are currently treated with glimepiride (Amaryl).
